
Evolvere BioSciences develops antibiotics designed to remain effective as bacteria evolve. The company uses AI-driven co-evolutionary models to predict resistance mechanisms and generate antimicrobial candidates. Its platform pairs computational drug discovery with medicinal chemistry and experimental validation in preclinical workflows. Evolvere operates as a biotech therapeutics developer collaborating with pharmaceutical partners and research institutions to address antibiotic resistance.

Evolvere BioSciences develops antibiotics designed to remain effective as bacteria evolve. The company uses AI-driven co-evolutionary models to predict resistance mechanisms and generate antimicrobial candidates. Its platform pairs computational drug discovery with medicinal chemistry and experimental validation in preclinical workflows. Evolvere operates as a biotech therapeutics developer collaborating with pharmaceutical partners and research institutions to address antibiotic resistance.
Headquarters: Oxford, Oxfordshire, United Kingdom
Focus: AI-driven discovery of next-generation antibiotics (co-evolutionary models)
Founded: 2021
Recent funding: Pre-Seed announced Sep 25, 2024; lead investor Y Combinator
Company size (reported): 1-10 employees
Antibiotic resistance; antimicrobial discovery
2021
Biotechnology
Round announced Sep 25, 2024; total amount reported as obfuscated in some profiles
“Y Combinator participation in Pre-Seed”